You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Urine Test for the Early Detection of Liver Cancer

    SBC: JBS SCIENCE INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of a urine test for the early detection of liver cancer The need to develop an effective method of detecting hepatocellular carcinoma HCC is urgent HCC is the third leading cause of cancer deaths and has a year survival rate of less than If HCC is identified early the survival rate can be as high as The survival rate drops significantly however to as l ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. In-Patient Pediatric Gastrojejunal Tube Cleaner Eliminating Surgical Intervention

    SBC: ACTUATED MEDICAL, INC.            Topic: NICHD

    DESCRIPTION provided by applicant In this Phase II NIH SBIR Actuated Medical Inc will complete the development of the Pedi GJ ClearTM device for clearing occlusions and restoring patency in situ to pediatric gastrojejunal feeding tubes GJ tubes eliminating the need to surgically replace clogged tubes Public Health Problem Enteral nutrition is provided for patients that have a functioning lower gas ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced In-Shoe Orthotic Treatment for Foot Pain

    SBC: DIAPEDIA, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): This Phase II SBIR proposal describes a strategy and work plan for accelerating to market a new device that will provide an evidence-based, patient-specific solution to a significant public health problem: foot pain. The TrueContour(R) therapeutic insole system was originally conceived for prevention of forefoot injury in diabetes mellitus. We propose to furth ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-Care HIV Antigen/Antibody Diagnostic Device

    SBC: Mbio Diagnostics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Actuated Low-Force Biopsy Tool for Versatile Bone Lesion Access with Less Trauma

    SBC: ACTUATED MEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II SBIR, Actuated Medical, Inc. will complete the development of the Actuated Low-Force Biopsy Tool for Versatile Bone Lesion Access with Less Trauma. Public Health Problem: Percutaneous bone biopsy is performed to obtain tissue for specific diagnosis of bone lesions identified through imaging or clinical evaluation. A major disadvantage of the ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to treat amyotrophic lateral sclerosis (ALS) and the many other conditions for which riluzole itself is un ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government